ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab/ocrelizumab in multiple sclerosis.

Marine Perriguey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.